A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

Inclusion Criteria: * Male or female, between 18 and 65 years age. * Biopsy-proven primary IgA nephropathy. * Currently on stable dose of ACEI and/or ARB therapy, for at least 12 weeks prior to screening (the patient's maximum tolerated dose and is at least one-half of the maximum labeled dose). * Average 24-hour urine total protein ≥ 0.75 g/24 h at screening. * Estimated GFR (using the CKD-EPI 2009) ≥ 30 mL/min per 1.73 m\^2 at screening. * Systolic BP between 100 and 150 mmHg and diastolic BP between 60 and 100 mmHg. Exclusion Criteria: * IgA nephropathy secondary to another condition * IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%; * Chronic kidney disease (CKD) in addition to IgAN * Patients treated with any systemic non-biologic immunosuppressive drugs (including systemic corticosteroids) within 12 weeks prior to randomizing； * Require any prohibited medications prior to randomizing; * Exposure to an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to screening * History of organ transplantation, with exception of corneal transplants * Platelet\< 100×109/L or hemoglobin value \< 90 g/L) or Hematocrit value \< 27% (0.27 V/V) at Screening * Elevations of transaminases (ALT and/or AST) \>2 times upper limit of normal or total bilirubin and/or direct bilirubin exceeding 1.5 times the upper limit of normal (ULN) at screening * Potassium \>5.5 mmol/L at Screening